At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Dasatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
In Brief
A Phase 2 clinical trial evaluating Dasatinib, Laboratory Biomarker Analysis, and 1 other intervention for Refractory Chronic Lymphocytic Leukemia and 4 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This phase II trial studies how well dasatinib works in treating patients with chronic lymphocytic leukemia (CLL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsOregon Health and Science University
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartOct 2011
Primary CompletionJul 2016
Study CompletionJan 2018
TodayJul 2026
First PostedSep 28, 2011
Enrollment StartOct 1, 2011
Primary CompletionJul 12, 2016
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.8 years ago
Interventions
Dasatinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies